Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
1st CP Inhibitor Approved for Sarcoma, Could This Be a Breakthrough to Treatment of More Subtypes?
Last week, Japan approved an immune checkpoint (CP) inhibitor for sarcoma for the first time, with the label expansion of Tecentriq (atezolizumab) into alveolar soft part sarcoma (ASPS). Specialists believe this will be a major step forward in the treatment…
To read the full story
Related Article
- Moves Being Made to Resolve Japan’s Drug Lag in Sarcoma: Oncologist
February 25, 2025
- Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
ACADEMIA
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…